RT Journal Article
SR Electronic
T1 Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.21.20159129
DO 10.1101/2020.07.21.20159129
A1 Nicholas C. Cullen
A1 Antoine Leuzy
A1 Sebastian Palmqvist
A1 Shorena Janelidze
A1 Erik Stomrud
A1 Pedro Pesini
A1 Leticia Sarasa
A1 José Antonio Allué
A1 Nicholas K. Proctor
A1 Henrik Zetterberg
A1 Jeffrey L. Dage
A1 Kaj Blennow
A1 Niklas Mattsson-Carlgren
A1 Oskar Hansson
YR 2020
UL http://medrxiv.org/content/early/2020/07/24/2020.07.21.20159129.abstract
AB We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI), using plasma biomarkers of β-amyloid (Aβ), tau, and neurodegeneration. We included MCI patients from the Swedish BioFINDER study (n=148) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI; n=86 for model selection; n=425 for prognostic validation). The primary outcomes were longitudinal cognition and conversion to AD dementia, predicted by plasma Aβ42/Aβ40, P-tau181, and neurofilament light (NfL). A model which included P-tau181 and NfL, but not Aβ42/Aβ40, had the best performance (AUC=0.88 for four-year conversion to AD in BioFINDER, validated in ADNI). The prognostic ability of plasma biomarkers was stronger than a basic model of age, sex, education, and baseline cognition and similar to cerebrospinal fluid biomarkers. Plasma biomarkers, in particular P-tau181 and NfL, may be of high value to identify MCI individuals who will progress to AD dementia in clinical trials and in clinical practice.Competing Interest StatementNC, AL, SP, SJ, NMC have nothing to disclose. OH has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, Eli Lilly and AVID Radiopharmaceuticals. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. NKP and JLD are employees and stockholders of Eli Lilly and Company.Clinical TrialNCT01208675, NCT00106899Funding StatementWork at the author's laboratory at Lund University was supported by the Swedish Research Council, the Wallenberg Center for Molecular Medicine, the Knut and Alice Wallenberg foundation, The Medical Faculty at Lund University, Region Skane, the Marianne and Marcus Wallenberg foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, the Swedish Medical Association, the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Bundy Academy, the Skane University Hospital Foundation, and the Swedish federal government under the ALF agreement. Data collection and sharing for the ADNI part of the study was funded by the Alzheimers Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants gave written informed consent. For BioFINDER, ethical approval was given by the Regional Ethical Committee of Lund University. Ethical approval in ADNI was given by the local ethical committees of all involved sites.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlasma and CSF data from ADNI were downloaded online at https://ida.loni.usc.edu. Anonymized data from the BioFINDER study will be shared by request from a qualified academic investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on the general data protection regulation and decisions by the Ethical Review Board of Sweden and Region Skane, which should be regulated in a material transfer agreement. The code used for statistical analyses is available at a public repository. https://brainapps.shinyapps.io/plasmaatnapp/